Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Sleek

Nurse Practitioner Bremen, GA Nurse Practitioner

NPI 1669982088 CMS profile 10631766

828 Pacific Ave, Bremen, GA 30110

Open in the dashboard

General payments

$5,001

319 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Sleek of Bremen, GA is reported in the CMS Open Payments database as having received $5,001 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,336 83
2024 General $595 38
2023 General $560 33
2022 General $1,068 65
2021 General $1,443 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Sleek
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Brittany Sleek were reported at $1,336. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Brittany Sleek Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,443 $135 $40–$426 $132
2022 $1,068 $152 $48–$470 $149
2023 $560 $166 $54–$529 $160
2024 $595 $173 $55–$556 $164
2025 $1,336 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,076 65 payments
  2. AbbVie, Inc. $1,021 100 payments
  3. Pfizer Inc. $508 27 payments
  4. Lilly USA, LLC $416 18 payments
  5. Amgen Inc. $397 25 payments
  6. GlaxoSmithKline, LLC. $203 13 payments
  7. Novartis Pharmaceuticals Corporation $186 9 payments
  8. AstraZeneca Pharmaceuticals LP $140 10 payments
  9. Amarin Pharma Inc. $114 5 payments
  10. Sanofi-Aventis U.S. LLC $112 6 payments
  11. Other $826 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,001 319 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $783 45 payments
  2. Ozempic $637 43 payments
  3. NURTEC ODT $472 25 payments
  4. QULIPTA $338 30 payments
  5. ELIQUIS $310 14 payments
  6. Otezla $303 19 payments
  7. MOUNJARO $248 8 payments
  8. VRAYLAR $244 37 payments
  9. UBRELVY $233 21 payments
  10. Repatha $211 14 payments
  11. Other $3,401 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

3,895

Median for Nurse Practitioner: 389

Drug cost

$493,706

Median for Nurse Practitioner: $21,885

Branded share of claims

22.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 122 $166,477
Mounjaro Tirzepatide Brand 68 $80,560
Jardiance Empagliflozin Brand 68 $68,006
Eliquis Apixaban Brand 16 $19,028
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $18,873
Vraylar Cariprazine Hcl Brand 14 $18,850
Trulicity Dulaglutide Brand 15 $15,822
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 11 $11,989
Praluent Pen Alirocumab Brand 17 $11,903
Rybelsus Semaglutide Brand 12 $10,980

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $50
$50 — —
VRAYLAR
  • AbbVie, Inc. $49
$49 14 —
QULIPTA
  • AbbVie, Inc. $45
$45 — —
ELIQUIS
  • PFIZER INC. $43
$43 16 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record